ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March

1 Mar 2016

Leuven, 1 March , 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, will host an “R&D Investor Meeting” in London focused on diabetic eye disease.
The meeting is intended for institutional investors and sell-side analysts and will feature clinical insights and expert views on diabetic eye disease, current treatments and key areas of unmet medical needs, provided by international experts:

• Prof Dr Reinier Schlingemann, Principal Investigator at the Medical Retina Unit and Ocular Angiogenesis Group, Department Of Ophthalmology at the AMC in Amsterdam, The Netherlands, and
• Prof Dr Alan Stitt, Centre Director of the Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, Ireland.

ThromboGenics CEO, Dr Patrik De Haes and senior members of ThromboGenics’ management team will provide an update of the Company’s strategy, its diabetic eye disease portfolio and its development plans.

Dr Patrik De Haes, CEO of ThromboGenics, commenting on today’s announcement, “This IR event is a great opportunity to outline for the first time the significant progress we have made in building an exciting drug development pipeline focused on diabetic eye disease. With the support of both Profs Schlingemann and Stitt we intend to explain how our novel pipeline products can address a number of the most pressing unmet medical needs of patients with diabetic eye disease.”

The event will take place on Friday, 18 March 2016 from 14:00 to 16:30 GMT at the offices of Citigate Dewe Rogerson’s offices, 3 London Wall Buildings , London EC2M 5SY.

To reserve a place, please email .